ReviewEndocrine connections2021
Treatment of malignancy-associated hypercalcemia with cinacalcet: a paradigm shift.
Review in Endocrine connections, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Malignancy-Associated Hypercalcemia and Kidney Disease: Facts, Controversies, and Management.Kidney medicine · 2026Review
- Endocrine paraneoplastic syndromes in lung cancer: A call for clinical vigilance (Review).Molecular and clinical oncology · 2025Review
- Parathyroid hormone-related protein levels and treatment outcomes in hypercalcemia of malignancy: a retrospective cohort study.JBMR plus · 2025Article
- Efficacy of Oral Cinacalcet in Non-PTH Nonmalignant Hypercalcemia from Excess 1,25-Dihydroxyvitamin D.JCEM case reports · 2024Article
- Calcitriol Unleashed: A Rare Culprit in Hypercalcemia Associated With Rare Primary Pancreatic Lymphoma - A Case Report.Journal of community hospital internal medicine perspectives · 2024Article
- Neurorescuing effect of Cinacalcet against hypercalcemia-induced nerve injury in chronic kidney disease via TRAF2/cIAP1/KLF2/SERPINA3 signal axis.Cell biology and toxicology · 2023Article
- Hypercalcemia of Malignancy Complicated by Osteonecrosis of the Jaw Treated With Cinacalcet.JCEM case reports · 2023Article
- Cinacalcet increases renal calcium excretion in PTHrP-mediated hypercalcemia: a case report.BMC endocrine disorders · 2023Article
- Refractory hypercalcemia of malignancy: a problem with many potential roots.Frontiers in endocrinology · 2023Article
- Cancer-related hypercalcemia and potential treatments.Frontiers in endocrinology · 2023Review
- Two-way Road of Kidney and Hypercalcemia: A Narrative Review.Cardiovascular & hematological disorders drug targets · 2023Review
- Article
- A Review of Current Clinical Concepts in the Pathophysiology, Etiology, Diagnosis, and Management of Hypercalcemia.Medical science monitor : international medical journal of experimental and clinical research · 2022Review
- Parathyroid Carcinoma All-In-One, a Rare Life-Threatening Case With Multiple Systemic Manifestations: Case Report and Review of the Literature.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Palliation of symptoms related to malignancy-associated hypercalcemia (MAH) is essential and clinically meaningful for patients, given the continued poor prognosis, with high morbidity and mortality associated with this disease process. Historically, agents have been temporizing, having no impact on patient morbidity nor survival. We suggest that cinacalcet can be an efficacious agent to be taken orally, reducing patients' time in the hospital/clinic settings. It is well-tolerated and maintains serum calcium levels in the normal range, while targeted cancer treatments can be employed. This has a direct, major impact on morbidity. Maintaining eucalcemia can increase quality of life, while allowing targeted therapies time to improve survival. Given that our case (and others) showed calcium reduction in MAH, there is promising evidence that cinacalcet can be more widely employed in this setting. Future consideration should be given to studies addressing the efficacy of cinacalcet in calcium normalization, improvement of quality of life, and impact on survival in patients with MAH. Though the exact mechanism of action for cinacalcet's reduction in calcium in this setting is not currently known, we can still afford patients the possible benefit from it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.